A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

BACKGROUND: Recent reports suggested combining ramucirumab with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to overcome EGFR resistance in non–small cell lung cancer (NSCLC). Nonetheless, evidence supporting the activity of afatinib and ramucirumab is lacking. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chun-Yao, Huang, Hui-Li, Lan, Chou-Chin, Huang, Yi-Chih, Wu, Yao-Kuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165754/
https://www.ncbi.nlm.nih.gov/pubmed/37158884
http://dx.doi.org/10.1186/s12885-023-10909-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165754/
https://www.ncbi.nlm.nih.gov/pubmed/37158884
http://dx.doi.org/10.1186/s12885-023-10909-z

Ejemplares similares